Drucken
vwd group

FRESENIUS MEDICAL CARE KGAA INHABER-AKTIEN O.N.

01.11.2017 - 18:35

DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care with strong contribution to research at world's largest gathering of kidney professionals



DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous


Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care with strong contribution to research at world's largest gathering of kidney professionals


01.11.2017 / 18:35



The issuer is solely responsible for the content of this announcement.



Fresenius Medical Care with strong contribution to research at world's largest gathering of kidney professionals


Fresenius Medical Care, the world's largest provider of dialysis products and services, today announced that company researchers and clinical experts from across the globe present 77 research abstracts at the 2017 American Society of Nephrology's (ASN) Kidney Week Symposium, the largest and most influential meeting of kidney professionals in the world.



Scheduled from October 31 to November 5, 2017, in New Orleans, Louisiana, USA, the annual symposium draws more than 13,000 physicians, scientists and healthcare professionals from over 100 countries.



"Our ability to harness the power of research across our global enterprise is one of our many competitive advantages," said Rice Powell, Chairman and Chief Executive Officer of Fresenius Medical Care. "Staying at the forefront of science drives our innovation and is central to better clinical outcomes in our core dialysis as well as in our care coordination activities."



The scope of the company's research and quality improvement endeavours builds on Fresenius Medical Care's strength as the world's largest vertically integrated healthcare company. With a focus on chronic kidney disease (CKD), end-stage renal disease (ESRD) and adjacent medical conditions, the company's research crosses seven general categories:



- Using science and technology to characterize and improve patient outcomes



- Driving advancements in management paradigms through value based care models



- Utilizing predictive modeling for clinical decision support and better outcomes



- Characterizing the impacts of CKD options education on outcomes and modality selection



- Leveraging coordinated care initiatives to improve patient outcomes



- Defining outcomes related to the management of bone mineral metabolism in renal disease



- Identification of the influences of social determinants of health on clinical measures



"The breadth and depth of our leadership in advancing science into clinical practice underscores our mission to improve the lives of people with kidney and chronic diseases," said Franklin W. Maddux, MD, Chief Medical Officer and Executive Vice President of Clinical and Scientific Affairs for Fresenius Medical Care North America. "In blending patient perspectives with real world evidence and traditional research, we are able to translate science into clinical practice that ultimately improves the lives of the patients who entrust us with their care."



Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,690 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 315,305 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).



For more information visit the Company's website at www.freseniusmedicalcare.com.



Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
















01.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE





 
End of News DGAP News Service





624213  01.11.2017 



fncls.ssp?fn=show_t_gif&application_id=624213&application_name=news&site_id=real_vwd

Zeit Kurs Vortag 1 Jahr
FMC 21:55 86,32 +0,86 +4,90%
Nachrichten
Zeit Meldung
17.05. DGAP-News: Fresenius Medical Care forecasts continued strong growth - Annual General Meeting approves 21st straight dividend increase
17.05. DGAP-News: Fresenius Medical Care weiter auf Wachstumskurs - Hauptversammlung beschließt 21. Dividendenerhöhung in Folge
03.05. DGAP-News: Fresenius Medical Care remains on track for another record year after solid first quarter 2018
22.04. DGAP-News: Fresenius Medical Care AG & Co. KGaA bestätigt das Wachstumsziel für das Konzernergebnis, passt das Wachstumsziel für den Umsatz für 2018 an und veröffentlicht vorläufige Ergebnisse für das 1. Quartal
22.04. DGAP-News: Fresenius Medical Care confirms net income growth target, adjusts 2018 revenue growth target and releases preliminary Q1 figures
22.04. DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target
22.04. DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA passt Ziel für Umsatzwachstum an und bestätigt Wachstumsziel für das Konzernergebnis 2018
21.04. DGAP-News: Fresenius Medical Care veräußert Sound Inpatient Physicians für 2,15 Milliarden US-Dollar - wichtiger Schritt zur strategischen Weiterentwicklung des Bereichs Versorgungsmanagement in den USA
21.04. DGAP-News: Fresenius Medical Care optimizes its U.S. Care Coordination portfolio and sells Sound Inpatient Physicians Holdings for $2.15 billion
21.04. DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sells Sound Inpatient Physicians Holdings for $2.15 billion

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de